Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$38.80M$38.80M+16.5% vs Q2 2016 Net Income-$13.23M-$13.23MN/M vs Q2 2016 EPS Diluted-$0.34-$0.34N/M vs Q2 2016 Operating Income-$13,598,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$5,248,000+31.5% Margins · derivedOperating margin-35.0%−0.9 pt vs Q2 2016
Net margin-34.1%+6.1 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end